Intensity Therapeutics Resumes Key Trials as Cash Runway Narrows — Intensity Therapeutics, Inc.

Event summary

Intensity Therapeutics resumed enrollment in its Phase 3 INVINCIBLE-3 soft tissue sarcoma study, using an FDA-reviewed amended protocol.
Patient treatment restarted in the Phase 2 INVINCIBLE-4 triple-negative breast cancer (TNBC) study after a dosing regimen revision.
Cash and cash equivalents stood at $9.5 million as of June 30, 2026, with $1.6 million raised under its ATM facility during Q2 2026.

The big picture

Intensity Therapeutics is navigating a critical phase in its clinical development, resuming key trials after pauses due to funding constraints. The company's focus on intratumoral cancer therapies aims to address unmet needs in aggressive cancers like TNBC and soft tissue sarcoma. Success in these trials could position Intensity as a player in the evolving landscape of targeted cancer treatments, but its ability to secure additional financing remains pivotal.

What we're watching

Trial Execution: Whether the amended protocols in INVINCIBLE-3 and INVINCIBLE-4 will accelerate patient enrollment and improve outcomes.
Financial Sustainability: The pace at which Intensity Therapeutics can raise additional capital to support its clinical trials, given its current cash runway.
Partnership Potential: How ongoing business development activities and interest from strategic partners may impact the company's future funding and trial advancements.